Skip to main content

Closed

RLYB: Rallybio Corporation Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+34.9% / yr

Operating margin-3278.2%

ROIC-55.8%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio12.92×

Rallybio Corporation

RLYBNASDAQ Capital Market·USD·Closed

Rallybio Corporation

RLYBNASDAQ·USD·Closed

$15.93

−0.87%

$15.93

−$0.14 (0.87%)

52W Range

89thpctl

Volume

0.07×avg

Mkt Cap

84.54MUSD

P/E

-10.7TTM

Div Yield

–ann

52W Range

89thpctl

Volume

0.07×avg

Market Cap

84.54MUSD

P/E Ratio

-10.7TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings